The Organ-on-a-Chip Industry is in the process of dynamic growth progressing due to the rise in headway in biomedical engineering, the upscale prerequisites of personalized therapy, and the continuous working on the new drug testing models which are more reliable and efficient. For instance, multi-organ-on-a-chip systems have come a long way from being a mere concept to an actual solution to certain medical issues. These revolutionary devices mimic the communication between different organs and permit scientists to follow the systemic effects of the drugs, related to more intricate physiological patterns and interactions. This thread exhibits a pattern of a pervasion of more rationalized and inclusive in vitro models, where there are fewer deviations from human body's functionalities depicting how drugs are developed and how diseases are modeled.
The market has been observing a significant increase in the number of different organs and tissues that are engineered into organ-on-a-chip devices. From the beginning of its development, the technologies mainly applied to the manufacture of simple tissue models. Lately, the technology became to encompass more complicated organ structure models, such as a liver, heart, lungs, and kidney models. This tendency is in line with the growing demand for multiple different and organ-specific in vitro systems carrying the aim to imitate both the functions and pathologies of certain organs and organ structures for different purposes, from drug test to disease modeling.
Additionally microfluidic and automation technologies are increasingly being incorporated in organ on a chip models. Microfluidic devices make it possible for us to achieve accurate control over fluid flows, nutrient delivery, and waste removal in the device itself, creating a close simulation of the dynamic environment of working organs. Adopting automation in conjunction by scientists contributes to reproducibility and uniformity of the experiments and makes adoptability of this technology for efficient use. This trend is an evidence of growing enthusiasm of developers to expand the technological capacities of organ-on-a-chip conducting systems in order to make them more carryouse friendly for researchers.
The market is now focusing on the utilization of personalized medicine applications with cells taken from human beings in organ-on-a-chip form. Such patient-derived models permit a lot of the clinicians to study clients reactions and response to all kinds of medication and treatments, but this helps a lot in the understanding of the types of drugs responses according to different patient population. It is also a mark of the shift towards the more personalized and patient-oriented methods in discovery and drug development as well as in illness study
Technical developments such as real-time sensors and sensor integration are generating the Organ-on-a-Chip Market paradigmn. Combination of sensors facilitates an ongoing gauge of various factors likecellular responses, metabolic activities, and drug effects, and therefore provides top-of-the-range data that is both dynamic and quantitative. This phenomenon takes a lead role in the development of a more comprehensive and time-sensitive analysis in the organ on the chip studies, which in turn improves the precision of the obtained outcomes.
Report Attribute/Metric | Details |
---|---|
Market Opportunities | Ability of OOC models to reduce drug development costs drastically and grants by government and non-government entities Key Market Drivers· Increasing investment by major companies in organ-on-a-chip research & development· The growing demand for drug screening with organs-on-a-chips |
The Organ-on-a-chip Market size is expected to reach USD 0.23 Billion by 2032 at 11.7% CAGR during the forecast period 2023-2032. Organs-on-chips (OOCs) are small plastic devices with biocompatible microfluidic chambers, which contain multiple live human cells in a 3D culture that simulate vital physiological functions of body organs. These cells are placed in an environment that artificially replicates aspects of the human body, such as morphology, movement, flow, electrical stimuli, and liquid gradients.
There has been an increase in the number of collaborative sales agreements between pharmaceutical companies and university spin-offs and the entry of new advanced models of OOCs into the market. The anticipated launch of advanced organ-specific models and human-on-chip models is expected to increase the growth rate of this Organ-On-a-Chip market in the future further.
The small size of the market is mainly because OOCs have not yet been fully commercialized. They are still in the research and development phase and are being used by a limited number of end-users.
There has been a notable rise in the prevalence of joint sales agreements between pharmaceutical corporations and university spin-offs, accompanied by the introduction of novel advanced models of organ-on-a-chip (OOC) systems onto the market. The future growth rate of the Organ-On-a-Chip market is likely to be further increased by the forthcoming development of enhanced organ-specific models and human-on-chip models. Furthermore, the market growth is expected to be driven by enhanced drug screening procedures, which have led to increased research and development activities by key industry players. Additionally, strategic efforts and developments in technology are also projected to contribute to the growth of the market in the forecast future.
The market growth is primarily influenced by two key factors: the significant cost reduction in drug development achieved via the use of organ-on-a-chip (OOC) models, and the availability of funds from both government and non-government groups. The projected growth at a high compound annual growth rate (CAGR) may be attributed to the growing number of collaborative sales agreements between pharmaceutical firms and university spin-offs, as well as the introduction of new sophisticated models of organ-on-a-chip (OOC) technology in the market. The future growth rate of the Organ On a Chip market is likely to be further enhanced by the forthcoming introduction of sophisticated organ-specific models and human-on-chip models.
September 2023, CN Bio, a prominent company specializing in Organ-on-a-Chip (OOC) technology for designing and producing microphysiological systems (MPS) with single and multiple organs, entered into a strategic partnership with LifeNet Health LifeSciences, also known as "LifeNet Health." LifeNet Health is a non-profit organization recognized globally for its expertise in all-human research solutions. The purpose of this collaboration is to provide CN Bio's PhysioMimix® OOC series of MPS with validated primary human cells. The agreement entails the inclusion of LifeNet Health's hepatic cells, which have been validated for high quality and MPS, in CN Bio's Non-Alcoholic Steatohepatitis (NASH) 'in-a-box' kit. Alternatively, customers can directly obtain these cells from LifeNet Health. This collaboration offers customers a simplified solution to replicate the advanced in vitro liver models developed by the Company and enhance the success of their assays.
The ability of OOC models to reduce drug development costs drastically and grants by government and non-government entities are the major factors influencing the market growth. It is expected to rise at this high CAGR due to an increase in the number of collaborative sales agreements between the pharmaceutical companies and university spin-offs and the entry of new advanced models of OOCs into the market. The anticipated launch of advanced organ-specific models and human-on-chip models is expected to further increase the growth rate of this Organ On a Chip market in the future. Grants by government and non-government entities have been the key drivers for the global OOC industry to date. The ability of OOC models to cut drug development costs drastically will be a key market driver in the future.
Moreover, improved drug screening methodologies increased R&D by major players, strategic initiatives and increasing technological advancements are also anticipated to fuel the market growth during the forecast period.
Drivers
Restraints
In January 2024,
In November 2023,
Emulate Inc. announces the launch of its new Liver-on-a-Chip platform, a microfluidic device that can be used to model liver function in vitro. The Liver-on-a-Chip platform is designed to provide researchers with a more accurate and reliable way to study liver diseases and develop new treatments.
InSphero AG announces the launch of its new Skin-on-a-Chip platform, a microfluidic device that can be used to model skin function in vitro. The Skin-on-a-Chip platform is designed to provide researchers with a more accurate and reliable way to study skin diseases and develop new treatments.
Organovo Inc. announces the launch of its new Ex Vivo Kidney platform, a bioengineered kidney that can be used to model kidney function in vivo. The Ex Vivo Kidney platform is designed to provide researchers with a more accurate and reliable way to study kidney diseases and develop new treatments.
Organ-On-a-Chip Market Key Players
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)